IL-6 is less studied and it is not known how IL-6 injections affect HSCs, but blocking IL-6 signaling inhibits expression of inflammatory genes in HSCs in response to LPS during neutropenia (25) or in response to murine hepatitis virus 1 (MHV-1) in mice or SARS-CoV2 in humans (26). Here, IL6 is linked to neutropenia.